Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 9/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | PYGM | P11217 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14509047 | 1.00 | CDA (0.58) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL3114394 | 1.00 | CDA (0.58) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL13519718 | 1.00 | CDA (0.58) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL399314 | 0.78 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL30241991 | 0.78 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6015184 | 0.78 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL11757296 | 0.78 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18512836 | 0.78 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18503564 | 0.78 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18512842 | 0.78 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772197-B2 | 1,3,5-triazines for treatment of viral diseases | 1,3,5-Triazines for Treatment of Viral Diseases (US) | 2010-08-10 | — | — | US | disclosed |
| US-7642247-B2 | 1,3,5-triazines for treatment of viral diseases | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070207973-A1 | 1,3,5-Triazines for Treatment of Viral Diseases | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1545558-A2 | 1, 3, 5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | Koronis Pharmaceuticals, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040127436-A1 | 1,3,5-Triazines for treatment of viral diseases | KORONIS PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| WO-2004028454-A2 | 1, 3, 5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207973-A1 | 1,3,5-Triazines for Treatment of Viral Diseases | HAVCR2, EIF2AK2, IKZF3 | CDA 688/4885MAPT 2447/4885SLC28A1 1923/4885 |
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | HAVCR2, EIF2AK2, IKZF3 | CDA 688/4885MAPT 2447/4885SLC28A1 1923/4885 |
| US-20040127436-A1 | 1,3,5-Triazines for treatment of viral diseases | HAVCR2, EIF2AK2, IKZF3 | CDA 688/4885MAPT 2447/4885SLC28A1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.